Africa’s journey to healthcare independence, as fueled by effects of the ongoing pandemic

RWANDA – As the world heads into the third year of the Covid-19 pandemic, health representatives globally are worried that the virus will outpace global effort to vaccinate large portions of the world population by the first half of 2022.

Despite initial commitments from the Covax global vaccine distribution mechanism to ship two billion doses by end of 2021, efforts have fallen short, with only about 1.45 billion doses expected by January.

Multiple factors such as failure to obtain regulatory authorization, India’s vaccines export ban in April and protracted negotiations with firms such as Moderna and Pfizer have contributed to the supply constraints.

At the current rate, it appears that neither the African Union’s goal of 60 percent vaccination by 2023 nor the World Health Organization’s (WHO) projection to hit the year-end target of fully vaccinating 40 per cent will be achieved.

Meanwhile, vaccine inequality is nothing new. When swine flu broke out in 2009, rich vaccine-producing countries refused to export jabs until domestic needs were met. In 2010, children in Morocco and Algeria missed out on life-saving meningitis vaccines amid a global shortage.


Now African leaders have resolved to ramp up local vaccine manufacturing. A high-level meeting by the Africa Centres for Disease Control and Prevention (Africa CDC) agreed to increase the manufacturing capacity for Covid-19 vaccines to ensure the continent does not lag behind in vaccinating its population.

As of September, there were at least 12 Covid-19 production facilities set up or in the pipeline across six African countries.

In June the WHO enlisted a team of South African researchers to crack the code for an mRNA Covid-19 vaccine following Moderna and Pfizer’s refusal to share their patent and then teach others around the world to make it. South Africa will be the first of several mRNA hubs, allowing more and more countries to produce vaccines.

Pfizer and German firm BioNTech in July announced a partnership with Biovac Institute in Cape Town to produce an mRNA-based Covid-19 jab. The partnership will see the giant pharmaceuticals transfer technology, install equipment and develop manufacturing capability. The first doses will be produced in 2022, the firms announced.

In October, BioNTech announced it has signed an agreement with the Rwandan government and Institut Pasteur de Dakar in Senegal to construct the first mRNA vaccine manufacturing facility in Africa starting in mid-2022. The plan is to initially build a production line with an annual capacity of 50 million doses that could be used to make vaccines for such diseases as malaria and tuberculosis as well as for Covid-19, Reuters reported.

This week Cuba expressed readiness to revive its plans to establish a vaccine manufacturing plant in Zimbabwe, which stalled due to the pandemic.

In Kenya, President Uhuru Kenyatta officially announced plans to set up a fill-finish vaccine plant known as Kenya Biovax Limited in the next six months.

Speaking to The EastAfrican, Kenya’s acting Director-General of Health Patrick Amoth said the government, through multi-stakeholder investments will pump in $17.8 million (Sh2 billion).

Our ultimate goal is to have a plant that will make a vaccine from design to market product,” said Dr Amoth.

Further, he mentioned that Korea had expressed readiness to support Kenya construct a human vaccine production facility at the Konza Technopolis. Private pharmaceuticals like Dawa Life Sciences are also throwing their hats into the ring with plans to set up a production plant for vaccines or injectables’ plant.” said Mwai Ngibuini, head of business development at Dawa Life Sciences in an interview with The EastAfrican.

Exports of AstraZeneca’s vaccine doses produced by the Serum Institute of India are expected to restart this month, filling part of the shortfall.

We have set the budget, identified the premises, worked out partnerships with successful plants so that we can build a plant that with capabilities to fill-finished to vials, labeled and packaged domestically,” said Dr Amoth, adding that He however declined to name the partners.

Fill and finish is the process of filling vials with vaccine and finishing the process of packaging the medicine for distribution.

On November 18, César Sanz Rodriguez — Moderna’s vice president of medical affairs for Europe, Middle East and Africa — in a meeting with African stakeholders was at pains to explain why the biotechnology company has been reluctant to share its patent to allow South African manufacturers to step up their production capacity.

But even with the hurdles, some countries have begun laying the ground work to develop the continent’s capacity.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.